<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A new combination of total lymphoid irradiation and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> was used prior to bone marrow transplantation in an attempt to achieve decreased rejection rates and <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Nine previously transfused patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> received marrow from an HLA-identical, MLC-compatible sibling following this preparative regimen </plain></SENT>
<SENT sid="2" pm="."><plain>There were no episodes of graft rejection, and only one patient developed <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Of the 9 patients, 7 (78%) are surviving with a median follow-up of 400 days </plain></SENT>
<SENT sid="4" pm="."><plain>The excellent results of this pretransplant combination of total lymphoid irradiation and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> warrants application of this regimen to a larger series of patients </plain></SENT>
</text></document>